We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Is AxoGen (AXGN) Stock Outpacing Its Medical Peers This Year?
Read MoreHide Full Article
The Medical group has plenty of great stocks, but investors should always be looking for companies that are outperforming their peers. Is AxoGen (AXGN - Free Report) one of those stocks right now? By taking a look at the stock's year-to-date performance in comparison to its Medical peers, we might be able to answer that question.
AxoGen is one of 1020 companies in the Medical group. The Medical group currently sits at #3 within the Zacks Sector Rank. The Zacks Sector Rank considers 16 different groups, measuring the average Zacks Rank of the individual stocks within the sector to gauge the strength of each group.
The Zacks Rank is a proven model that highlights a variety of stocks with the right characteristics to outperform the market over the next one to three months. The system emphasizes earnings estimate revisions and favors companies with improving earnings outlooks. AxoGen is currently sporting a Zacks Rank of #2 (Buy).
Over the past three months, the Zacks Consensus Estimate for AXGN's full-year earnings has moved 10.6% higher. This is a sign of improving analyst sentiment and a positive earnings outlook trend.
According to our latest data, AXGN has moved about 110% on a year-to-date basis. Meanwhile, the Medical sector has returned an average of -4.4% on a year-to-date basis. As we can see, AxoGen is performing better than its sector in the calendar year.
Boston Scientific (BSX - Free Report) is another Medical stock that has outperformed the sector so far this year. Since the beginning of the year, the stock has returned 52.3%.
In Boston Scientific's case, the consensus EPS estimate for the current year increased 2.5% over the past three months. The stock currently has a Zacks Rank #2 (Buy).
Breaking things down more, AxoGen is a member of the Medical - Instruments industry, which includes 86 individual companies and currently sits at #58 in the Zacks Industry Rank. Stocks in this group have gained about 3.1% so far this year, so AXGN is performing better this group in terms of year-to-date returns.
On the other hand, Boston Scientific belongs to the Medical - Products industry. This 87-stock industry is currently ranked #82. The industry has moved +8.8% year to date.
AxoGen and Boston Scientific could continue their solid performance, so investors interested in Medical stocks should continue to pay close attention to these stocks.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Is AxoGen (AXGN) Stock Outpacing Its Medical Peers This Year?
The Medical group has plenty of great stocks, but investors should always be looking for companies that are outperforming their peers. Is AxoGen (AXGN - Free Report) one of those stocks right now? By taking a look at the stock's year-to-date performance in comparison to its Medical peers, we might be able to answer that question.
AxoGen is one of 1020 companies in the Medical group. The Medical group currently sits at #3 within the Zacks Sector Rank. The Zacks Sector Rank considers 16 different groups, measuring the average Zacks Rank of the individual stocks within the sector to gauge the strength of each group.
The Zacks Rank is a proven model that highlights a variety of stocks with the right characteristics to outperform the market over the next one to three months. The system emphasizes earnings estimate revisions and favors companies with improving earnings outlooks. AxoGen is currently sporting a Zacks Rank of #2 (Buy).
Over the past three months, the Zacks Consensus Estimate for AXGN's full-year earnings has moved 10.6% higher. This is a sign of improving analyst sentiment and a positive earnings outlook trend.
According to our latest data, AXGN has moved about 110% on a year-to-date basis. Meanwhile, the Medical sector has returned an average of -4.4% on a year-to-date basis. As we can see, AxoGen is performing better than its sector in the calendar year.
Boston Scientific (BSX - Free Report) is another Medical stock that has outperformed the sector so far this year. Since the beginning of the year, the stock has returned 52.3%.
In Boston Scientific's case, the consensus EPS estimate for the current year increased 2.5% over the past three months. The stock currently has a Zacks Rank #2 (Buy).
Breaking things down more, AxoGen is a member of the Medical - Instruments industry, which includes 86 individual companies and currently sits at #58 in the Zacks Industry Rank. Stocks in this group have gained about 3.1% so far this year, so AXGN is performing better this group in terms of year-to-date returns.
On the other hand, Boston Scientific belongs to the Medical - Products industry. This 87-stock industry is currently ranked #82. The industry has moved +8.8% year to date.
AxoGen and Boston Scientific could continue their solid performance, so investors interested in Medical stocks should continue to pay close attention to these stocks.